NLRP4–ER Stress–CCL5 axis as a translational target for NK cell-based immunotherapy in lung cancer

The human body possesses a sophisticated internal defense force, a network of immune cells constantly patrolling for signs of infection or abnormal growth. Among these defenders are natural killer cells, a specialized type of white blood cell that acts as a rapid-response unit. Unlike other immune cells that require specific training to recognize a threat, natural killer cells are ready to attack immediately upon detecting a tumor or a virus-infected cell. However, in many solid cancers, such as lung cancer, these powerful cells face a significant obstacle: they simply cannot find their way into the tumor. The tumor creates a hostile environment that blocks entry, leaving the natural killer cells stranded outside while the cancer grows unchecked. This inability to infiltrate the tumor site remains a major bottleneck in modern cancer treatment, limiting the success of therapies designed to harness the body's own immune system.

Researchers at Shanghai Jiao Tong University have identified a specific molecular pathway that could help solve this problem of getting immune cells inside the tumor. They focused on a protein called NLRP4, which is found in lung cancer cells. In healthy tissue, this protein is present, but in lung tumors, its levels are often much lower. The team discovered that when they increased the amount of NLRP4 inside lung cancer cells, it triggered a chain reaction that acted like a beacon, calling natural killer cells directly to the tumor. This process did not rely on the body's T cells, another type of immune defender, but worked specifically through the natural killer cells, which are crucial for attacking solid tumors.

To understand how this beacon worked, the scientists looked for the proteins that NLRP4 interacts with inside the cell. They found that NLRP4 binds directly to a protein called BIP, which normally helps the cell manage stress caused by the accumulation of misfolded proteins. When the researchers increased NLRP4 levels, it altered the activity of BIP, leading to a state of cellular stress that caused the cancer cell to release a chemical signal known as CCL5. This signal is a chemoattractant, a substance that draws specific cells toward its source. The study showed that the CCL5 released by the cancer cells specifically attracted natural killer cells, guiding them from the bloodstream into the tumor tissue. Once inside, these cells became more active and began to attack the cancer.

The team tested this mechanism in living mice to see if it could stop tumor growth. They used two different types of mice: some with human immune systems and others with mouse immune systems. In both cases, when they introduced cancer cells that overproduced NLRP4, the tumors grew much slower than in control groups. The tumors that shrank were filled with natural killer cells, while the number of other immune cells, such as T cells, remained unchanged. This confirmed that the effect was driven specifically by the natural killer cells. Furthermore, when the researchers blocked the natural killer cells in the mice, the anti-tumor effect disappeared completely, proving that these cells were the essential agents of the cure.

To make the effect even stronger, the scientists combined the NLRP4 increase with a drug called HA15, which inhibits the BIP protein. This combination created a powerful synergy. In the mice, the tumors shrank significantly more with the combination treatment than with either approach alone. The researchers observed that this dual approach did not cause weight loss or other signs of toxicity in the animals, suggesting it could be a safe way to boost the immune response. The study also showed that the drug HA15 alone could increase the release of the CCL5 signal, but pairing it with NLRP4 overexpression made the effect much more potent.

The researchers also examined the specific type of immune cells that responded to the CCL5 signal. They found that while the signal strongly attracted natural killer cells, it did not significantly move other types of white blood cells, such as neutrophils or B cells, into the tumor. This selectivity is important because it means the therapy targets the most effective killers without unnecessarily activating other parts of the immune system that might cause inflammation without helping. The study confirmed that the CCL5 signal not only brought the natural killer cells to the tumor but also helped them become more aggressive, increasing their ability to destroy cancer cells.

This work suggests a new way to think about treating lung cancer. Instead of trying to force the immune system to attack, the strategy involves changing the cancer cells themselves so they send out a signal that invites the immune system in. By manipulating the NLRP4 protein and the stress response pathways inside the tumor, it is possible to turn a "cold" tumor, which ignores the immune system, into a "hot" one that attracts natural killer cells. The study provides a clear mechanism for how this happens: NLRP4 interacts with BIP, which leads to the release of CCL5, which in turn recruits and activates natural killer cells.

The findings offer a potential path forward for immunotherapy, particularly for patients whose tumors do not respond to current treatments. While the study was conducted in mice and cell cultures, the results point to a specific biological axis that could be targeted in humans. The researchers noted that the interaction between NLRP4 and BIP creates a positive feedback loop, where the arrival of natural killer cells further stimulates the immune response, potentially leading to sustained tumor control. This approach does not rely on the complex machinery of T cells, which often struggle in solid tumors, but instead leverages the innate power of natural killer cells.

The study also highlighted that this mechanism works across different types of lung cancer cells, including both mouse and human cell lines. This consistency suggests that the pathway is fundamental to how these cells behave, rather than being a fluke of a single cell type. The researchers used various methods to confirm their findings, including genetic engineering to increase protein levels, drugs to block specific interactions, and detailed imaging to see where the cells were located. They also measured the levels of the chemical signals in the tumor fluid to ensure the mechanism was active.

One of the most significant aspects of this discovery is the identification of a specific target for drug development. The protein BIP is already known to scientists, and drugs that inhibit it, like HA15, are available. This means that the combination of increasing NLRP4 and using existing drugs to modulate BIP could be tested relatively quickly. The study showed that this combination was more effective than either method alone, suggesting that targeting multiple steps in the same pathway could yield better results.

The research also addressed a common concern in immunotherapy: whether boosting one type of immune cell might suppress others. The data showed that increasing NLRP4 and inhibiting BIP did not reduce the number of T cells or other immune cells in the tumor. Instead, it specifically enhanced the presence and activity of natural killer cells. This specificity is crucial for developing therapies that are effective without causing widespread immune disruption.

In the broader context of cancer research, this work adds a new piece to the puzzle of how tumors evade the immune system. It shows that the tumor's own internal stress management systems can be hijacked to turn the tumor against itself. By understanding the role of NLRP4 and its connection to cellular stress, scientists can design strategies to exploit this weakness. The study does not claim to have solved lung cancer, but it provides a clear, testable hypothesis for how to improve the delivery of immune cells to the tumor site.

The researchers concluded that the NLRP4-BIP-CCL5 axis represents a promising target for future therapies. They emphasized that while the mechanism is now understood in mice, further work is needed to see if it works the same way in humans. However, the clarity of the pathway and the availability of tools to manipulate it make it a strong candidate for further investigation. The study offers a hopeful direction for overcoming the limitations of current immunotherapies, suggesting that by simply changing the chemical signals a tumor emits, it is possible to invite the body's own defenses to do the work of destroying the cancer.